GO
Loading...

Medicine

More

  • The buyout offer from Swiss drug giant Roche has shares of DNA trading at their highest level in about two-and-a-half years and according to CNBC stock-stat maven, Robert Hum, if they close up at least 8.88% it'll be their biggest one-day percentage gain since April 15, 2005.

  • Teva & Barr Get Super-Sized Friday, 18 Jul 2008 | 1:59 PM ET
    The Horsham, Pa., offices of Teva Pharmaceuticals North America are shown Monday, July 25, 2005.   In a deal that will create the world's largest generic drug company, Teva Pharmaceutical Industries Ltd. said Monday it is acquiring rival Ivax Corp. for about $7.4 billion (6.13 billion euros) in cash and stock. Ivax shares climbed 10 percent in morning trading.  (AP Photo/George Widman)

    arr's Chairman and CEO Bruce Downey told me Teva's CEO Schlomo Yanai made the first move. But it didn't happen in a long-distance phone call from Tel Aviv to New Jersey. They say they were at an industry conference in Palm Beach outside some burger joint when the subject came up.

  • Teva to Buy Barr for $7.5 Billion, Boosts Generic Lead Friday, 18 Jul 2008 | 10:41 AM ET
    The Horsham, Pa., offices of Teva Pharmaceuticals North America are shown Monday, July 25, 2005.   In a deal that will create the world's largest generic drug company, Teva Pharmaceutical Industries Ltd. said Monday it is acquiring rival Ivax Corp. for about $7.4 billion (6.13 billion euros) in cash and stock. Ivax shares climbed 10 percent in morning trading.  (AP Photo/George Widman)

    Teva Pharmaceutical Industries said on Friday it would buy rival generic drugmaker Barr Pharmaceuticals for $7.46  billion to expand its leadership in the U.S. market and fortify its presence in Europe.

  • Lilly's Sex Survey: Will It Have Desired Effect On Cialis? Wednesday, 16 Jul 2008 | 12:31 PM ET
    Lilly

    More than ten years after Pfizer brought Viagra to market and brought erectile dysfunction out of the closet a new survey says a lot of men are still too embarrassed to talk about impotence with their doctor.

  • Genentech Regenerates Avastin Tuesday, 15 Jul 2008 | 10:59 AM ET

    After a knee-jerk reaction to the downside after the closing bell yesterday to the surprising four-cent miss by Genentech, the shares are rallying big time in the early regular trading session.

  • Bobby Murcer Remembered Monday, 14 Jul 2008 | 10:43 AM ET
    Bobby Murcer as New York Yankees broadcaster

    Like so many people who knew Bobby Murcer or were fans of his, I was so sad to hear the news that he had passed away. I didn't know the man. And I only have vague childhood memories of then-Dodger Stadium announcer John Ramsey saying, "Bobby Murcer", when the "Yankee for Life" was playing for the Giants and Cubs at Chavez Ravine.

  • Elan In Double Trouble? Friday, 11 Jul 2008 | 11:32 AM ET
    Elan

    A few weeks ago I blogged about a couple analysts cautioning investors that shares of Irish drugmaker Elan would be volatile surrounding the Alzheimer's conference the end of this month.That has certainly proven to be the case, especially today as the second firm this week initiates coverage of the stock, but this time with a "Sell" rating.

  • Pfizer, Merck And Lilly Partner Up To Get "Enlightened" Thursday, 10 Jul 2008 | 10:30 AM ET

    Big pharma makes strange bedfellows. Pfizer, Merck and Eli Lilly this morning announced they've launched a joint venture of sorts called, "Enlight Biosciences". They're doing it with the help of the Boston-based VC firm PureTech Ventures.

  • Big Pharma Stocks: Real Rally Or One Day Wonder? Wednesday, 9 Jul 2008 | 11:19 AM ET
    Pharma Stocks

    One day does not a full-fledged sector rotation make, but yesterday the big pharma stocks put on a show and in the early going today the curtain hasn't fallen. Pfizer even broke above 18 bucks!

  • Cowen's "Elan" For Elan Tuesday, 8 Jul 2008 | 9:49 AM ET
    Elan

    At the risk of being ganged up on by the "Elanians" who will take umbrage with the fact that the biopharma team at Cowen and Company is not initiating coverage of the Irish drugmaker with a "screaming buy," I am blogging about the analysts' 50-page call on the stock today.

  • UBS And Its Guarded Outlook For Merck's Gardasil Monday, 7 Jul 2008 | 11:14 AM ET

    Shares of Merck, which have lost more than a third of their value so far this year, are under continued pressure this morning. They were at 60 bucks in early January. Today they're trading around $37. Big pharma analyst Rupesh Patel at UBS is downgrading the Dow component from Buy to Neutral because he thinks it's gonna be "range-bound near-term"...

  • Readers Get Short With Me--Over Amgen Thursday, 3 Jul 2008 | 11:08 AM ET

    Ahead of the long holiday weekend I thought this would be as good a time as any to once again go through the "Pharma's Market" mailbag. A couple of blog readers complained about my "short" story about Amgen.

  • Biopharma Analyst Musical Chairs Wednesday, 2 Jul 2008 | 11:16 AM ET

    In the world of nearly 400 publicly-traded biotechs, analyst coverage is especially important. Many of the firms are micro caps and when an analyst initiates coverage it can help put a baby biotech on investor and reporter radar screens.

  • A "Short" Story On Amgen Monday, 30 Jun 2008 | 9:04 AM ET
    AMGEN

    When combing through Barron's over the weekend I always make it a point to check out the "Short Interest" tables when they appear. I'm curious, in particular, about the ups and downs in Dendreon. Right now it's 39th on Barron's list of the Top-40 largest short positions.

  • Merck Muscles In On Migraines Friday, 27 Jun 2008 | 4:29 PM ET

    On another ugly day for the stock markets, beaten down shares of Dow component Merck rallied. The stock started picking up steam after the news broke late this morning that its late-stage experimental migraine headache drug essentially works just as well as an existing drug, but with fewer side effects.

  • Fourth of July fireworks

    FBR's Christopher Warren is out with a research note to clients this morning saying that Boston Scientific is doing deals. He writes that BSX is "reportedly bundling $1,100 (that's right, $1,100) Taxus stents with defibrillators and ultrasound devices."

  • sCredit Suisse building sign

    Credit Suisse is out today with a "fat" report on obesity. Nearly 200 pages. But besides its size, the research also stands out as one of the most unique pieces of Wall Street analysis I've ever seen.

  • FDA Delivers One-Two Punch To Merck & Lilly Wednesday, 25 Jun 2008 | 11:11 AM ET
    FDA

    For the second time in three days the Food and Drug Administration has delayed making a decision on drugs that it had put on a fast track. First, the agency put off a ruling on Lilly's bloodthinner Effient and then this morning Merck announced the FDA is not ready to approve its cervical cancer vaccine Gardasil for older women.

  • Lilly's Effient Empire Tuesday, 24 Jun 2008 | 10:49 AM ET

    Tree huggers (just a colloquialism, not a dig) will be glad to know that biopharmaceutical companies submit their Food and Drug Administration filings for drug approval electronically these days.

  • Pfizer and the State of Statins Monday, 23 Jun 2008 | 11:15 AM ET

    As much as I tried to disconnect during my vacation last week, I couldn't escape the ubiquitous presence of pharmaceuticals in our everyday lives...